Hoffmann-La Roche GO28667, A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients with Chronic Lympocytic Leukemia to Evaluate the Benefit of GDC-0199 (ABT-199) Plus Rituximab Compared with Bendamustine Plus Rituximab
Cancer - Leukemia
Principal Investigator: Nalini Janakiraman, MD
This open-label, randomized study will compare the efficacy of GDC-0199 plus rituximab with bendamustine plus rituximab in patients with relapsed or resistant chronic lymphocytic leukemia.
At least 18 years of age; diagnosis of chronic lymphocytic leukemia which is relapsed or refractory; previously treated with 1-3 lines of therapy including at least one standard chemotherapy-containing regimen.